2025 Q2 - tulosraportti
387 päivää sitten
‧20 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 116 | - | - | ||
| 80 | - | - | ||
| 108 | - | - | ||
| 200 | - | - | ||
| 444 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 - tulosraportti 27.8.2025 | ||
2025 Q1 - tulosraportti 30.4.2025 | ||
2024 Q4 - tulosraportti 27.2.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·14 t sitten · MuokattuANALYSIS FROM YESTERDAY (17.09): Oncoinvent ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. There is no resistance in the price chart and a further increase is indicated. Positive volume balance strengthens the stock in the short term. The short-term momentum in the stock is strongly positive, with RSI over 70. This indicates increasing optimism among investors and further price increase for Oncoinvent ASA.
Very exciting and I am convinced that this will be the next biotech rocket on the Oslo Stock Exchange. A new Circio-race is underway👌😊
·15 t sitten · MuokattuWhat happens if sales were to completely dry up and the initial selling interest would be at plus, e.g., 40 %? What do the regulations/rules then say about how long trading can be postponed? In the case of Oncin with only 4.7 million shares and enormous upside potential, the question is probably not too surreal. At this price level, news can hit with a complete repricing.
1 päivä sittenFrom FA CAN THE OPPENHEIMER SUMMIT TODAY GIVE ONCOINVENT A NEW START? Today, Oncoinvent is on stage at the Oppenheimer Targeted Radiopharmaceutical Therapies Summit . And that could be an important turning point. Oppenheimer values Radspherin's potential peak sales at around $1.94 billion , equivalent to approximately NOK 19.7 billion , for the first two indications. With Oppenheimer's 7–10× peak-sales multiple, this corresponds to a potential value of NOK 138–197 billion , while the market value is around NOK 0.6 billion. The market currently values Oncoinvent at 0.3-0.4% of the values Oppenheimer's scenario suggests. The mechanism of action of alpha emitters is well documented. Radspherin is designed to cleave DNA in micrometastases, while its extremely short range limits the impact on surrounding healthy tissue. Oppenheimer focuses on what Radspherin could be worth – not just what Oncoinvent is worth today. The market has previously shown that it takes this difference into account when acquiring alpha-emitting companies. Today's Summit could help elevate Oppenheimer's much higher valuation calculation around Oncoinvent into the international medical community. The case should be very relevant, not least for Big Pharma. Being the sole supplier of a highly effective cancer treatment without dose-limiting toxicity – for a platform targeting cancer in the peritoneal cavity – should be an overwhelmingly interesting goal for Big Pharma.
The problem with this post is not that it is optimistic, but that it appears to be directly incorrect – and thus, in my opinion, detrimental to the case. I would very much like to see a concrete reference to where Oppenheimer is supposed to have used 7–10x peak sales on Oncoinvent. Everything I have seen for a de-risked biotech company with one main product rather points towards around 3–5x peak sales. With patent life and other assumptions, 7–10x appears very difficult to defend. That peak sales could be much higher if Radspherin eventually proves to be a platform that works in multiple cancer types, is of course another matter. But then the sales basis itself increases – one does not need to inflate the multiple in addition. I therefore do not understand the need to construct a hypothetical future valuation of 138–197 billion kroner when the potential is already very large with much more conservative assumptions. Such posts, in my view, do more harm than good. When undocumented or erroneous figures are presented as if they come from Oppenheimer, it weakens credibility and makes shareholders appear less serious.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2025 Q2 - tulosraportti
387 päivää sitten
‧20 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sitten · MuokattuANALYSIS FROM YESTERDAY (17.09): Oncoinvent ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. There is no resistance in the price chart and a further increase is indicated. Positive volume balance strengthens the stock in the short term. The short-term momentum in the stock is strongly positive, with RSI over 70. This indicates increasing optimism among investors and further price increase for Oncoinvent ASA.Very exciting and I am convinced that this will be the next biotech rocket on the Oslo Stock Exchange. A new Circio-race is underway👌😊
- ·15 t sitten · MuokattuWhat happens if sales were to completely dry up and the initial selling interest would be at plus, e.g., 40 %? What do the regulations/rules then say about how long trading can be postponed? In the case of Oncin with only 4.7 million shares and enormous upside potential, the question is probably not too surreal. At this price level, news can hit with a complete repricing.
- 1 päivä sittenFrom FA CAN THE OPPENHEIMER SUMMIT TODAY GIVE ONCOINVENT A NEW START? Today, Oncoinvent is on stage at the Oppenheimer Targeted Radiopharmaceutical Therapies Summit . And that could be an important turning point. Oppenheimer values Radspherin's potential peak sales at around $1.94 billion , equivalent to approximately NOK 19.7 billion , for the first two indications. With Oppenheimer's 7–10× peak-sales multiple, this corresponds to a potential value of NOK 138–197 billion , while the market value is around NOK 0.6 billion. The market currently values Oncoinvent at 0.3-0.4% of the values Oppenheimer's scenario suggests. The mechanism of action of alpha emitters is well documented. Radspherin is designed to cleave DNA in micrometastases, while its extremely short range limits the impact on surrounding healthy tissue. Oppenheimer focuses on what Radspherin could be worth – not just what Oncoinvent is worth today. The market has previously shown that it takes this difference into account when acquiring alpha-emitting companies. Today's Summit could help elevate Oppenheimer's much higher valuation calculation around Oncoinvent into the international medical community. The case should be very relevant, not least for Big Pharma. Being the sole supplier of a highly effective cancer treatment without dose-limiting toxicity – for a platform targeting cancer in the peritoneal cavity – should be an overwhelmingly interesting goal for Big Pharma.The problem with this post is not that it is optimistic, but that it appears to be directly incorrect – and thus, in my opinion, detrimental to the case. I would very much like to see a concrete reference to where Oppenheimer is supposed to have used 7–10x peak sales on Oncoinvent. Everything I have seen for a de-risked biotech company with one main product rather points towards around 3–5x peak sales. With patent life and other assumptions, 7–10x appears very difficult to defend. That peak sales could be much higher if Radspherin eventually proves to be a platform that works in multiple cancer types, is of course another matter. But then the sales basis itself increases – one does not need to inflate the multiple in addition. I therefore do not understand the need to construct a hypothetical future valuation of 138–197 billion kroner when the potential is already very large with much more conservative assumptions. Such posts, in my view, do more harm than good. When undocumented or erroneous figures are presented as if they come from Oppenheimer, it weakens credibility and makes shareholders appear less serious.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 116 | - | - | ||
| 80 | - | - | ||
| 108 | - | - | ||
| 200 | - | - | ||
| 444 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 - tulosraportti 27.8.2025 | ||
2025 Q1 - tulosraportti 30.4.2025 | ||
2024 Q4 - tulosraportti 27.2.2025 |
Välittäjätilasto
Dataa ei löytynyt
2025 Q2 - tulosraportti
387 päivää sitten
‧20 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 - tulosraportti 27.8.2025 | ||
2025 Q1 - tulosraportti 30.4.2025 | ||
2024 Q4 - tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sitten · MuokattuANALYSIS FROM YESTERDAY (17.09): Oncoinvent ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. There is no resistance in the price chart and a further increase is indicated. Positive volume balance strengthens the stock in the short term. The short-term momentum in the stock is strongly positive, with RSI over 70. This indicates increasing optimism among investors and further price increase for Oncoinvent ASA.Very exciting and I am convinced that this will be the next biotech rocket on the Oslo Stock Exchange. A new Circio-race is underway👌😊
- ·15 t sitten · MuokattuWhat happens if sales were to completely dry up and the initial selling interest would be at plus, e.g., 40 %? What do the regulations/rules then say about how long trading can be postponed? In the case of Oncin with only 4.7 million shares and enormous upside potential, the question is probably not too surreal. At this price level, news can hit with a complete repricing.
- 1 päivä sittenFrom FA CAN THE OPPENHEIMER SUMMIT TODAY GIVE ONCOINVENT A NEW START? Today, Oncoinvent is on stage at the Oppenheimer Targeted Radiopharmaceutical Therapies Summit . And that could be an important turning point. Oppenheimer values Radspherin's potential peak sales at around $1.94 billion , equivalent to approximately NOK 19.7 billion , for the first two indications. With Oppenheimer's 7–10× peak-sales multiple, this corresponds to a potential value of NOK 138–197 billion , while the market value is around NOK 0.6 billion. The market currently values Oncoinvent at 0.3-0.4% of the values Oppenheimer's scenario suggests. The mechanism of action of alpha emitters is well documented. Radspherin is designed to cleave DNA in micrometastases, while its extremely short range limits the impact on surrounding healthy tissue. Oppenheimer focuses on what Radspherin could be worth – not just what Oncoinvent is worth today. The market has previously shown that it takes this difference into account when acquiring alpha-emitting companies. Today's Summit could help elevate Oppenheimer's much higher valuation calculation around Oncoinvent into the international medical community. The case should be very relevant, not least for Big Pharma. Being the sole supplier of a highly effective cancer treatment without dose-limiting toxicity – for a platform targeting cancer in the peritoneal cavity – should be an overwhelmingly interesting goal for Big Pharma.The problem with this post is not that it is optimistic, but that it appears to be directly incorrect – and thus, in my opinion, detrimental to the case. I would very much like to see a concrete reference to where Oppenheimer is supposed to have used 7–10x peak sales on Oncoinvent. Everything I have seen for a de-risked biotech company with one main product rather points towards around 3–5x peak sales. With patent life and other assumptions, 7–10x appears very difficult to defend. That peak sales could be much higher if Radspherin eventually proves to be a platform that works in multiple cancer types, is of course another matter. But then the sales basis itself increases – one does not need to inflate the multiple in addition. I therefore do not understand the need to construct a hypothetical future valuation of 138–197 billion kroner when the potential is already very large with much more conservative assumptions. Such posts, in my view, do more harm than good. When undocumented or erroneous figures are presented as if they come from Oppenheimer, it weakens credibility and makes shareholders appear less serious.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 116 | - | - | ||
| 80 | - | - | ||
| 108 | - | - | ||
| 200 | - | - | ||
| 444 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt